培氟沙星治疗原发肾病综合征临床初探

Clinical Research on Pefloxacin-Treated Patients with Primary Nephrotic Syndrome

用培氟沙星和强的松对17例原发肾病综合征患者进行疗效观察。培氟沙星治疗组24小时尿蛋白下降及血浆白蛋白升高,均较治疗前有较显著变化(P<0.05,P<0.01)。其有效率为75.0％,与强的松组比较无显著性差异(78％,P=0.48)。提示培氟沙星与强的松疗效相近,且毒副作用少,具有成为治疗原发肾病综合征一线药物的潜在价值。其治疗机制可能与对T细胞亚群及白介素2的调节有关。

Seventeen patients with primary nephrotic syndrome (PNS) were treated either with pefloxacine (Pef) or with prednisone (P). Proteinuria (Upro/24h) was decreased and serum albumin was increased remarkably in Pef group (P<0. 05,P<0. 01). The effectiveness rate of Pef group was 6/8, but there was no marked difference between Pef and P groups (7/9, P>0. 05). It was concluded that the curative effect was similar with P whereas its side effects were much less. The lowering of protein-uria of the patients may be the results of Pef regulating T-cell subgroup and concentration of IL-2. Pef may have potential value as first-line drug for treating PNS patients.